Lymphoproliferative syndrome
MONDO:0016537A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).
Also known as: lymphoproliferative disorder, lymphoproliferative syndrome
138 clinical trials for this condition and its sub-types, 70 tagged with Lymphoproliferative syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphoproliferative syndrome
-
Castleman disease 8 trials · 18 incl. sub-types
4 sub-types
- Multicentric Castleman disease 13 trials
- Idiopathic multicentric Castleman disease 3 trials Sub-types →
- Localized Castleman disease 1 trial
- Pediatric Castleman disease 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types
2 sub-types
-
Lymphoproliferative syndrome 1 0 trials
-
Lymphoproliferative syndrome 2 0 trials
-
Immunotherapy blinatumomab shows promise in kids with relapsed leukemia
Disease control CompletedThis Phase 3 trial tested the drug blinatumomab in 111 children with high-risk relapsed B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is an immunotherapy that helps the body's immune cells attack cancer cells. The study compared blinatumomab to standard chemotherap…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aims to cut steroid use in lung sarcoidosis
Disease control CompletedThis Phase 3 trial tested a drug called efzofitimod in 268 adults with pulmonary sarcoidosis, a condition that causes lung inflammation. Participants received either the drug or a placebo every 4 weeks for 48 weeks. The main goal was to see if the drug could help people safely re…
Phase 3 • Sponsor: aTyr Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New immune combo shows promise against stubborn lymphoma
Disease control CompletedThis study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shr…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Needle vs. IV: which isatuximab method works best for myeloma?
Disease control CompletedThis study tested whether a shot under the skin (subcutaneous) works as well as an IV drip for the drug isatuximab in people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. All participants also received standard chemotherapy. The goal was to se…
Phase 3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immune cell therapy shows promise for Post-Transplant cancer
Disease control CompletedThis study tested whether specially treated donor white blood cells could help treat a type of lymph cancer that sometimes occurs after an organ transplant. The cancer is linked to the Epstein-Barr virus. Fifty transplant recipients took part. The goal was to see if adding these …
Phase 3 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for Hard-to-Treat blood cancer
Disease control CompletedThis study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC